Edition:
United Kingdom

Selecta Biosciences Inc (SELB.OQ)

SELB.OQ on NASDAQ Stock Exchange Global Market

11.98USD
23 May 2018
Change (% chg)

$0.18 (+1.53%)
Prev Close
$11.80
Open
$11.99
Day's High
$12.84
Day's Low
$11.72
Volume
91,275
Avg. Vol
86,172
52-wk High
$24.00
52-wk Low
$8.00

Chart for

About

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of... (more)

Overall

Beta: --
Market Cap(Mil.): $435.97
Shares Outstanding(Mil.): 22.07
Dividend: --
Yield (%): --

Financials

  SELB.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -2.86 -- --
ROI: -59.00 1.57 14.38
ROE: -72.01 2.43 16.07

BRIEF-Selecta Biosciences Announces Q1 Loss Per Share $0.71

* SELECTA BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Selecta Biosciences Qtrly Loss Per Share $0.88

* SELECTA BIOSCIENCES ANNOUNCES FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

15 Mar 2018

BRIEF-Selecta Appoints ‍Gabriel Pirona As New Chief Financial Officer

* ‍HUGUES ROUGIER WILL RESIGN FROM HIS ROLE AS CHIEF FINANCIAL OFFICER

14 Mar 2018

BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018

* SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING

08 Jan 2018

BRIEF-Selecta Biosciences Says CEO Werner Cautreels Plans Retirement at 2018 End

* SELECTA BIOSCIENCES ANNOUNCES CEO’S INTENT TO RETIRE AND TRANSITION PLAN

02 Jan 2018

BRIEF-Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy

* SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY

02 Jan 2018

Earnings vs. Estimates